Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 21Urinary Bladder Neoplasms 8Biliary Tract Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 6Nasopharyngeal Carcinoma 6Nasopharyngeal Neoplasms 5Cholangiocarcinoma 5Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Cancer Resectable 2Neoplasm Metastasis 2Lymphoma, Extranodal NK-T-Cell 2Thyroid Neoplasms 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rare Tumour 1Pancreatic cancer, adult 1Pancreatic Cancer Non-resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Mibc 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Pancreatic Cancer 1Liver Neoplasms 1Klatskin Tumor 1

Interventions

Gemcitabine 2sintilimab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Cancer Resectable × Gemcitabine × Clear all
NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡